#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,1 Gomella LG,2 Sharma P,3 Plimack ER,4 O’Donnell PH,5 Hoffman-Censits J,2 Flaig TW,6 Quinn DI,7 Campogan D,8 Haynes H,8 McCoy C,8 Maher J,8 DeVries T,8 Sheikh N,8 and Lerner SP9 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 NeuACT poster 4541 thumb

1Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA, USA; 3University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Fox Chase Cancer Center, Philadelphia, PA, USA; 5The University of Chicago, Chicago, IL, USA; 6University of Colorado, Denver, CO, USA; 7University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; 8Dendreon Corporation, Seattle, WA, USA; 9Baylor College of Medicine, The Scott Department of Urology, Houston, TX, USA